HF
ACAD icon

HRT Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

HRT Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,070
Closed -$855K – 3099
2025
Q3 		$855K Buy
+40,070
New +$948K ﹤0.01% 1609
2025
Q1 		– Sell
-92,926
Closed -$1.71M – 2443
2024
Q4 		$1.71M Buy
92,926
+40,558
+77% +$655K 0.01% 811
2024
Q3 		$805K Sell
52,368
-123,451
-70% -$2.06M ﹤0.01% 1358
2024
Q2 		$2.86M Buy
175,819
+141,756
+416% +$2.29M 0.02% 598
2024
Q1 		$629K Sell
34,063
-276,499
-89% -$6.85M ﹤0.01% 1138
2023
Q4 		$9.72M Buy
310,562
+281,165
+956% +$6.71M 0.07% 165
2023
Q3 		$612K Buy
+29,397
New +$798K 0.01% 1287
2023
Q2 		– Sell
-257,237
Closed -$4.84M – 2362
2023
Q1 		$4.84M Buy
+257,237
New +$4.9M 0.06% 264
2022
Q3 		– Sell
-55,918
Closed -$787K – 2707
2022
Q2 		$787K Buy
55,918
+14,020
+33% +$262K 0.01% 1095
2022
Q1 		$1.01M Sell
41,898
-92,531
-69% -$2.24M 0.01% 1013
2021
Q4 		$3.14M Buy
+134,429
New +$2.7M 0.02% 448
2020
Q4 		– Sell
-65,259
Closed -$2.69M – 1775
2020
Q3 		$2.69M Sell
65,259
-29,948
-31% -$1.29M 0.08% 173
2020
Q2 		$4.61M Buy
+95,207
New +$4.57M 0.14% 138

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

HRT Financial's ACAD Position: Q4 2025 in Review

HRT Financial sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 40,070 shares — an estimated $855K sold.

HRT Financial first reported a position in ACAD in Q2 2020 and held it in 13 quarters. The position peaked at $9.72M in Q4 2023. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • HRT Financial reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 40,070 Acadia Pharmaceuticals shares in Q4 2025, an estimated $855K.
  • HRT Financial first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • HRT Financial's Acadia Pharmaceuticals position peaked at $9.72M in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.